Paolo Magni, Tijana Mitić, Yvan Devaux, Philippe Pierre, Miron Sopić, Fernando de la Cuesta, Rui Vitorino
{"title":"解读动脉粥样硬化中的免疫动力学:炎症介质作为生物标志物和治疗靶点。","authors":"Paolo Magni, Tijana Mitić, Yvan Devaux, Philippe Pierre, Miron Sopić, Fernando de la Cuesta, Rui Vitorino","doi":"10.1111/eci.70043","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Atherosclerosis, one of the main causes of cardiovascular disease, is driven by complex interactions between lipid metabolism and immune mechanisms in the vascular system. Regulatory molecules, particularly protein fragments derived from cytokines, chemokines and other immune-related proteins, play a central role in modulating inflammation and immune responses in atherosclerotic plaques.</p><p><strong>Results: </strong>Recent advances in peptidomics have revealed the dual role of immune system-derived peptides as indicators and effectors of atherosclerotic cardiovascular disease (ASCVD). Certain subsets of immune cells, such as pro-inflammatory monocytes and regulatory T cells, contribute to this peptide-mediated regulation. New findings suggest that these peptides may serve as diagnostic biomarkers and therapeutic targets in atherosclerosis.</p><p><strong>Conclusion: </strong>This review highlights the translational relevance of immune-mediated peptides in ASCVD and emphasizes their diagnostic and therapeutic potential. By integrating peptidomics with immunology research, a new framework for understanding and targeting inflammation in atherosclerosis is proposed, opening new avenues for precision medicine in cardiovascular care.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70043"},"PeriodicalIF":4.4000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Deciphering immune dynamics in atherosclerosis: Inflammatory mediators as biomarkers and therapeutic target.\",\"authors\":\"Paolo Magni, Tijana Mitić, Yvan Devaux, Philippe Pierre, Miron Sopić, Fernando de la Cuesta, Rui Vitorino\",\"doi\":\"10.1111/eci.70043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Atherosclerosis, one of the main causes of cardiovascular disease, is driven by complex interactions between lipid metabolism and immune mechanisms in the vascular system. Regulatory molecules, particularly protein fragments derived from cytokines, chemokines and other immune-related proteins, play a central role in modulating inflammation and immune responses in atherosclerotic plaques.</p><p><strong>Results: </strong>Recent advances in peptidomics have revealed the dual role of immune system-derived peptides as indicators and effectors of atherosclerotic cardiovascular disease (ASCVD). Certain subsets of immune cells, such as pro-inflammatory monocytes and regulatory T cells, contribute to this peptide-mediated regulation. New findings suggest that these peptides may serve as diagnostic biomarkers and therapeutic targets in atherosclerosis.</p><p><strong>Conclusion: </strong>This review highlights the translational relevance of immune-mediated peptides in ASCVD and emphasizes their diagnostic and therapeutic potential. By integrating peptidomics with immunology research, a new framework for understanding and targeting inflammation in atherosclerosis is proposed, opening new avenues for precision medicine in cardiovascular care.</p>\",\"PeriodicalId\":12013,\"journal\":{\"name\":\"European Journal of Clinical Investigation\",\"volume\":\" \",\"pages\":\"e70043\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-04-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Clinical Investigation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/eci.70043\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/eci.70043","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Deciphering immune dynamics in atherosclerosis: Inflammatory mediators as biomarkers and therapeutic target.
Background: Atherosclerosis, one of the main causes of cardiovascular disease, is driven by complex interactions between lipid metabolism and immune mechanisms in the vascular system. Regulatory molecules, particularly protein fragments derived from cytokines, chemokines and other immune-related proteins, play a central role in modulating inflammation and immune responses in atherosclerotic plaques.
Results: Recent advances in peptidomics have revealed the dual role of immune system-derived peptides as indicators and effectors of atherosclerotic cardiovascular disease (ASCVD). Certain subsets of immune cells, such as pro-inflammatory monocytes and regulatory T cells, contribute to this peptide-mediated regulation. New findings suggest that these peptides may serve as diagnostic biomarkers and therapeutic targets in atherosclerosis.
Conclusion: This review highlights the translational relevance of immune-mediated peptides in ASCVD and emphasizes their diagnostic and therapeutic potential. By integrating peptidomics with immunology research, a new framework for understanding and targeting inflammation in atherosclerosis is proposed, opening new avenues for precision medicine in cardiovascular care.
期刊介绍:
EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.